Novartis AG
NVS
$119.14
$0.590.50%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.26B | 51.72B | 50.32B | 48.59B | 47.55B |
| Total Other Revenue | 1.92B | 1.50B | 1.41B | 1.35B | 1.31B |
| Total Revenue | 55.19B | 53.22B | 51.72B | 49.94B | 48.86B |
| Cost of Revenue | 13.10B | 12.95B | 12.82B | 12.08B | 11.96B |
| Gross Profit | 42.09B | 40.27B | 38.90B | 37.86B | 36.90B |
| SG&A Expenses | 13.13B | 12.78B | 12.56B | 12.48B | 12.44B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 264.00M | 524.00M | 750.00M | 160.00M | 445.00M |
| Total Operating Expenses | 36.43B | 35.95B | 35.88B | 32.10B | 33.76B |
| Operating Income | 18.75B | 17.27B | 15.84B | 17.84B | 15.10B |
| Income Before Tax | 15.61B | 14.92B | 13.64B | 12.73B | 10.90B |
| Income Tax Expenses | 1.97B | 2.06B | 1.70B | 975.00M | 814.00M |
| Earnings from Continuing Operations | 13.64K | 12.86K | 11.94K | 11.76K | 10.09K |
| Earnings from Discontinued Operations | -- | -- | -- | 5.84B | 6.09B |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 16.00M | -1.00M | 2.00M | 4.00M | -2.00M |
| Net Income | 13.65B | 12.86B | 11.94B | 17.60B | 16.18B |
| EBIT | 18.75B | 17.27B | 15.84B | 17.84B | 15.10B |
| EBITDA | 22.12B | 20.61B | 19.18B | 22.17B | 19.59B |
| EPS Basic | 6.91 | 6.43 | 5.92 | 8.63 | 7.90 |
| Normalized Basic EPS | 5.70 | 5.21 | 4.71 | 5.28 | 4.42 |
| EPS Diluted | 6.86 | 6.39 | 5.88 | 8.58 | 7.86 |
| Normalized Diluted EPS | 5.66 | 5.17 | 4.68 | 5.25 | 4.39 |
| Average Basic Shares Outstanding | 7.92B | 8.00B | 8.08B | 8.14B | 8.19B |
| Average Diluted Shares Outstanding | 7.97B | 8.06B | 8.13B | 8.19B | 8.24B |
| Dividend Per Share | 3.86 | 3.86 | 3.86 | 3.92 | 3.92 |
| Payout Ratio | 57.26% | 60.27% | 63.85% | 43.31% | 47.13% |